WO2026062561 - METHODS AND COMPOSITIONS FOR TREATING GENITAL PSORIASIS
National phase entry is expected:
Publication Number
WO/2026/062561
Publication Date
26.03.2026
International Application No.
PCT/IB2025/059391
International Filing Date
18.09.2025
Title **
[English]
METHODS AND COMPOSITIONS FOR TREATING GENITAL PSORIASIS
[French]
MÉTHODES ET COMPOSITIONS POUR TRAITER LE PSORIASIS GÉNITAL
Applicants **
SUN PHARMACEUTICAL INDUSTRIES LIMITED
Inventors
NISHANDAR, Tushar Bhimrao
MEHTA, Shantanu
SOULE, Benjamin P
HONCZARENKO, Marek
Priority Data
202421071226
20.09.2024
IN
202521068869
18.07.2025
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4497 | |
| EPO | Filing, Examination, Granting | 70635 | |
| Japan | Filing, Examination, Granting | 4282 | |
| South Korea | Filing, Examination, Granting | 6421 | |
| USA | Filing, Examination, Granting | 28340 |
Total:
114,175
Contact Us
Abstract[English]
The disclosure relates to methods of treating genital psoriasis comprising administering an anti-IL-23p19 antibody hum13B8-b to a patient in need thereof. The disclosure also relates to pharmaceutical compositions of an anti-IL-23p19 antibody hum13B8-b or antigen binding fragment thereof for the treatment of genital psoriasis in a patient. The disclosure further relates to the use of an anti-IL-23p19 antibody hum13B8-b or antigen binding fragment thereof for the manufacture of a medicament for treating genital psoriasis in a patient.[French]
La présente divulgation concerne des méthodes de traitement du psoriasis génital comprenant l'administration d'un anticorps anti-IL-23p19 hum13B8-b à un patient en ayant besoin. La présente divulgation concerne également des compositions pharmaceutiques d'un anticorps anti-IL-23p19 hum13B8-b ou d'un fragment de liaison à l'antigène de celui-ci pour le traitement du psoriasis génital chez un patient. La présente divulgation concerne en outre l'utilisation d'un anticorps anti-IL-23p19 hum13B8-b ou d'un fragment de liaison à l'antigène de celui-ci pour la fabrication d'un médicament destiné au traitement du psoriasis génital chez un patient.